Metrics as of 10/13/2026, 06:49 PM (Berlin time), refresh in progress.
Sintx Technologies, Inc.
Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, primarily marketed across the United States. Its diverse portfolio…
1D
-11.6%
1W
-15.7%
1M
+2.2%
6M
-33.2%
YTD
-52.6%
1Y
-56.5%
2Y
-41.2%
5Y
-100.0%
10Y
-100.0%
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~33% stronger price swings than usual
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 01/10/2026
P/E
-0.34
P/B
1.88
EV/EBITDA
-1.07
RETURN ON EQUITY
-56.0%
NET MARGIN
-598.7%
DEBT/EQUITY
0.63
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
84.1%
FLOAT SHARES
5,348,680
AVG. DAILY VOLUME (30D)
69,541
Sintx Technologies, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Eric K. Olson, the company employs around 32 people.
The IPO was on 13/02/2014; the stock trades on NASDAQ under the ticker SINT.
3 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
No, Sintx Technologies currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess Sintx Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.